Akero Therapeutics' Upcoming Presentations at AASLD 2024
In an exciting announcement, Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company renowned for developing innovative treatments for serious metabolic diseases, is set to present new findings at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting for 2024. Taking place in San Diego, from November 15-19, 2024, these presentations will provide significant insights into the efficacy of efruxifermin (EFX), the company's lead product candidate.
Highlights from the HARMONY Study
The presentations will feature data collected from the 96-week Phase 2b HARMONY study, which examined the effects of efruxifermin on patients suffering from metabolic dysfunction-associated steatohepatitis (MASH), specifically those in fibrosis stage 2 or 3. The findings aim to demonstrate not only the efficacy in improving liver fibrosis but also the safety of EFX in this patient population.
Key Presentation Details
One of the prominent presentations titled "Efruxifermin Significantly Improved Liver Fibrosis at Week 96 in the HARMONY Study Across Subgroups and Improvements Were Associated With Changes in Biomarkers" will be delivered by Dr. Mazen Noureddin, a well-respected professor of medicine at Houston Methodist Hospital. This oral session is scheduled for November 17, 2024, from 2:00 PM to 2:15 PM PST.
Late-Breaking Poster Presentations
In addition, Dr. Noureddin will also lead two late-breaking poster presentations on November 18, 2024. The first poster is titled "Efruxifermin significantly reduced the proportion of subjects with at-risk MASH and led to near-complete histological disease reversal at week 96 in the HARMONY study," showcasing the remarkable impacts of EFX treatment. The second poster will explore "AI and digital-based pathology corroborate reduction in fibrosis observed by conventional pathology with efruxifermin treatment of patients with F2-F3 MASH in the HARMONY study." These presentations emphasize a comprehensive analysis using advanced digital tools, reinforcing the credibility of the study results.
About Akero Therapeutics
Akero Therapeutics is at the forefront of clinical development for revolutionary treatments aimed at serious metabolic diseases. They continue to push the boundaries with their lead product candidate, EFX, which is currently subject to rigorous scrutiny in ongoing trials. The SYMMETRY study is a pivotal 96-week Phase 2b clinical trial focusing on patients with compensated cirrhosis due to MASH (F4 fibrosis). Moreover, the company is also conducting three expansive Phase 3 clinical trials under the SYNCHRONY program, which focus on patients experiencing pre-cirrhotic MASH or compensated cirrhosis.
The Path Forward for MASH Treatments
The advancements achieved through previous Phase 2 trials, like the HARMONY study, pave the way for a brighter future in managing MASH conditions. The insights derived from comprehensive research not only contribute to treatment efficacy but also open doors for new therapeutic avenues explored through sophisticated methods such as AI in pathology.
Company Vision and Commitment
Headquartered in South San Francisco, Akero Therapeutics is dedicated to addressing high unmet medical needs with a patient-centric approach. Their commitment is evident in their ongoing research, which seeks to transform the landscape of treatment for patients suffering from metabolic diseases, particularly regarding liver health and development.
Frequently Asked Questions
What is efruxifermin?
Efruxifermin is a therapeutic candidate developed by Akero Therapeutics aimed at treating metabolic dysfunction-associated steatohepatitis (MASH).
When will Akero present its findings at AASLD 2024?
Akero will present findings during the AASLD 2024 conference, scheduled from November 15-19, 2024, with specific presentations on November 17 and 18.
Who is presenting the data on efruxifermin?
Dr. Mazen Noureddin will present the data, showcasing his expertise as a professor of medicine at Houston Methodist Hospital.
What is the significance of the HARMONY study?
The HARMONY study is crucial as it evaluates the effectiveness of efruxifermin in improving liver fibrosis in patients with MASH, demonstrating potential for significant clinical impact.
How can I learn more about Akero Therapeutics?
You can find more information about Akero Therapeutics and their ongoing studies by visiting their official website at akerotx.com or following them on their social media platforms.
